The distribution of the 11 post-chemotherapy profile changes was not linked to any other clinicopathological parameter (age, tumour grade, tumour stage, ESR1 status, ERBB2 status and type of incomplete pathological response) and was not linked to the pre-treatment TP53 status of the tumours. The gene discussed is TP53; the disease is neoplasm.